# US 2026/0217729 A1 · Halogen-substituted exatecan amide derivative, preparation method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217729 A1
- Document ID: US20260217729A1
- Status: Published application
- Kind: A1
- Application number: 19/578,962
- Filed: 2026-03-26
- Published: 2026-07-30
- Earliest claimed: 2023-09-28
- Assignees: Hangzhou Adcoris Biopharma Co., Ltd
- Applicants: Hangzhou Adcoris Biopharma Co., Ltd
- Inventors: Zhenwei MIAO; Yunsheng Huang
- Web page: https://patentgrep.com/patent/US20260217729A1

## CPC

- C07D 491/22: in which the condensed system contains four or more hetero rings
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A halogen-substituted exatecan amide derivative, a preparation method therefor, and a use thereof are provided; the halogen-substituted exatecan amide derivative or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof has good cancer cell inhibitory activity and activity across the cell membrane, and can be applied to the treatment of cancer as a single drug, a combined drug, or a toxin component of an ADC.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof:
in the Formula, R is selected from any one of C1-C6 alkyl, halogen-substituted C1-C6 alkyl,
wherein, R1 is selected from C1-C6 alkylene, the C1-C6 alkylene is optionally substituted with one or more substituents selected from halogen, C1-C6 alkyl or halogen-substituted C1-C6 alkyl;
R2 is selected from any one of halogen, C1-C6 alkyl or halogen-substituted C1-C6 alkyl; X is selected from any one of amino, imino.

### Claim 2 (depends on 1)

The compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, wherein, R1 is selected from methylene, halogen-substituted methylene or trifluoromethyl-substituted methylene;
preferably, R1 is selected from —CHF—, —CHF2—, —CH2— or —CH(CF3)—.

### Claim 3 (depends on 1)

The compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, wherein, R2 is selected from any one of halogen, methyl, methylene, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, heptyl; preferably, any one of methylene, methyl, ethyl, isopropyl;
the halogen is selected from any one of —F, —Cl, —Br, —I, preferably —F.

### Claim 4 (depends on 1)

The compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, wherein, X is selected from —NH— or —NH2.

### Claim 5 (depends on 1)

The compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, wherein,
is selected from
wherein, R1 is selected from halogen; preferably F;
n is selected from 1, 2, 3 or 4, preferably, n is 1;
preferably, R is selected from

### Claim 6 (depends on 1)

The compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, wherein, the compound of formula (I) is any one of the following compounds:

### Claim 7 (depends on 1)

A method for preparing the compound according to claim 1, comprising:
reacting halogen-substituted carboxylic acid, carboxylic anhydride, or acyl chloride with exatecan to prepare the compound;
preferably, the halogen-substituted carboxylic acid, carboxylic anhydride, or acyl chloride is selected from any one of 2-fluoromalonic acid, 2-amino-3,3,3-trifluoropropanoic acid, difluoroacetic anhydride, 2,2-difluoropropanoic acid.

### Claim 8 (depends on 1)

An antibody-drug conjugate, comprising a small molecule drug, a linker, and an antibody, wherein, the small molecule drug comprises the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, or an antibody-drug conjugate comprising a small molecule drug, a linker, and an antibody, wherein, the small molecule drug comprises the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.

### Claim 10 (depends on 1)

A method for treating a cancer, comprising the step of administering to a patient in need thereof the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof according to claim 1, an antibody-drug conjugate comprising a small molecule drug, a linker, and an antibody, wherein, the small molecule drug comprises the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or an antibody-drug conjugate;
preferably, the cancer comprises any one of gastric cancer, esophageal cancer, esophagus cancer, breast cancer, breast adenocarcinoma, lung cancer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein in the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof,
is selected from
wherein, R1 is selected from halogen; preferably F;
n is selected from 1, 2, 3 or 4, preferably, n is 1;
preferably, R is selected from

### Claim 12 (depends on 10)

The method according to claim 10, wherein in the compound, or pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, the compound of formula (I) is any one of the following compounds:
